semaglutide nejm weight loss Oral 25 mg and Orforglipron for Obesity: New Insights Tirzepatide vs Semaglutide: 2025 NEJM

FDA Commissioner Makary publicly endorsed the deal, and the resolution may serve as a template for how other telehealth companies navigate the evolving regulatory landscape

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra

Nauck MA, DAlessio DA

1 The side effects were consistent with what you'd expect from GLP-1-class drugs: nausea, diarrhea, constipation, and decreased appetite were the most common

Given the heterogeneity of study designs and outcomes, results were synthesized using a narrative approach

322 MurugaiyanGda CunhaAPAjayAKJollerNGaroLPKumaradevanSet al